+91-8668442535

Direct to Consumer Microbiome Analyzing Market By Product Type (Gut Microbiome Test Kits, Other Microbiome Testing Kits & Health Sample Kits) By Application (Infections, Gut Conditions, Metabolic Disorders, Cardiovascular Disease, Others) - Growth, Future Prospects and Competitive Landscape, 2016 – 2028

What are the merits of enhanced diagnostic testing and clinical microbiome analysis based on sequencing?

Human microbiomes play an important part in modern healthcare since they perform numerous activities such as facilitating food digestion, regulating the immune system, and producing vitamins such as Vitamin K, Vitamin B, and Vitamin B12. Human microbiome improves immunity and nutrition, among other things. According to an article published in the International Journal of Microbiology, in May 2020, the human microbiome has recently gained prominence due to its link with a variety of respiratory disorders and immunity. The gut microbiota has been linked to a person's immunity. The direct to consumer microbiome analysis tests measure the number of species present in the gut microbiome as well as their ability to manufacture vitamins and butyrate. This vital short-chain fatty acid helps to keep your gut lining healthy. Different bacteria ratios in your gut can affect your level of protection against obesity, type 2 diabetes, Crohn's disease, ulcerative colitis, and coronary heart disease.

Microbiome analyzers look at a person's intestinal DNA to see if he or she has a genetic propensity to certain diseases. It aids in the improvement of the individual's gut health by providing required dietary advice for balancing the microbiome. Probiotics and beneficial bacteria report, dietary fibre breakdown and butyrate synthesis, and individualised meal recommendations are among the tests available. Advances in diagnostic testing, as well as sequencing-based clinical microbiome analysis, will boost future growth. Direct to consumer DNA testing is rapidly developing, and it can diagnose particular infections, lifestyle diseases, and gastrointestinal problems such as irritable bowel syndrome and inflammatory bowel disease. For instance, SmartGut (uBiome, Inc.), is the world's first sequencing-based clinical microbiome diagnostic. To accommodate future active demand, global giants are investing in additional R&D and pushing the production of these sample kits in collaboration with smaller enterprises. In June 2019, Atlas Biomed Group Limited (personalised health Technology Company) introduced its DNA and Microbiome test products in Canada, following significant performance in the European market.

direct-to-consumer-microbiome-analyzing-market.img1

What is the Market Size of Direct to Consumer Microbiome Analyzing in terms of value?

The global Direct to Consumer Microbiome Analyzing Market is projected to increase at a significant CAGR of 11.50% in the coming years. In 2021, the global Direct to Consumer Microbiome Analyzing market was valued at USD XX billion and is projected to reach at the value of USD XX billion by 2028. The demand for Direct to Consumer Microbiome Analyzing is projected to increase substantially in the coming years and is presumed to generate revenue opportunities for the key industry players worth USD XX billion during the forecast period of 2022 and 2028.

What Makes the Human Microbiome so Important for Human Survival?

There are many microorganisms in the human body. A group of microorganisms makes up the human microbiome. Fungi, bacteria, and archaea are among these microbes. Recent developments in DNA sequencing technology have enabled a more thorough analysis of these bacteria and their evolving intimate connections with their hosts. The microbiome is crucial for metabolic and developmental processes in the human body, including as food digestion, vitamin synthesis, and brain function, according to scientists and experts. Different bacteria ratios in your gut can influence your risk of obesity, type 2 diabetes, Crohn's disease, ulcerative colitis, and coronary heart disease. From 3 microbiome samples in 2010 to 123,302 microbiome samples in 2020, the number of human microbiome samples with publicly available data has been steadily expanding. The Human Microbiome Project (HMP) identified 60 million genes, 600 microbial reference genomes, and 700 metagenomes, whereas the MetaHIT database has 3.3 million non-redundant human microbiome genes in practically every collection of genes for the human gut microbiome.

Interesting Facts about Direct to Consumer Microbiome Analyzing Industry

  • Increasing gastrointestinal issues, technological advancements, rising investments in human microbiome projects in emerging countries, and the profitable presence of market players internationally are driving the rapid rise of the global direct to consumer human microbiome analysis market. The market will expand throughout the forecast period due to the rising frequency of genetic illnesses and many applications of direct to consumer microbiome analysis in the primary identification of oncology, infections, chronic diseases, and other genetic disorders.
  • North America region had a major share in terms of volume as well as value in the global Direct to Consumer Microbiome Analyzing market in 2021 and it is expected to maintain its dominance during the forecast period.
  • The launch of SmartGut and Viome Gut IntelligenceTM Test will boost revenue growth during the predicted period. The growing number of collaborations, strong pipeline products for direct to consumer microbiome analysis, and higher personal care expenditure in developing countries will boost overall market growth.
  • Companies, labourites, and associations are collaborating to assess challenges and identify opportunities for Direct to Consumer Microbiome Analyzing R&D.

Who are the Top 10 players/companies in the Direct to Consumer Microbiome Analyzing market in term of value?

The key players in the global Direct to Consumer Microbiome Analyzing market in terms of value include uBiome, Inc., Viome, Inc., Atlas Biomed Group Limited, Quantbiome, Inc. (Thryve Personalize), FINCH THERAPEUTICS, MaaT Pharma Kallyope Inc. and others. These key players are concentrating on new product developments as well as technological innovation to enhance their production in Direct to Consumer Microbiome Analyzing to gain competitive market share at a global level. For instance, in September 2021, PhenoBiome has launched a human gut microbiome assay, which will be processed at Genetic Direction's CLIA- and CAP-certified laboratory. On the other hand, in 2019, Seres cooperated with AstraZeneca to get a deeper knowledge of the microbiome in enhancing cancer immunotherapy efficacy, including possible synergy with AstraZeneca drugs.

Who are the Top 10 Countries in the Direct to Consumer Microbiome Analyzing Market?

In the global Direct to Consumer Microbiome Analyzing market, the major countries are US, Canada, Mexico, China, Japan, South Korea, Germany, France, Russia, and UK. The largest market share is in United States. The growing population, fresh FDA approvals, and the presence of major players keep the United States in a leading position. The genetics industry has recognised consumer interest in microbiome testing as an opportunity, and a number of prominent commercial laboratories are distributing these test kits directly on a global scale, mostly in the United States market. Personalised health technology businesses in the United States are gaining headway in the genomics market, and they also educate their customers about the importance of big data in their personal care. Many human microbiome-based product companies have received funding to help them develop therapeutic medications faster. For instance, in 2020, Finch Therapeutics (US) raised USD 90 million in Series D financing from new and current investors to advance CP101 through the final stages of clinical development and regulatory filing in Clostridioides difficile infection. The funds will also be utilised to enhance the company's platform and pipeline, including the start of Phase 1b trials on FIN-211 for autistic spectrum disorder (ASD) and CP101 for chronic hepatitis B. (HBV). These financing and investments focusing on microbiome research for medicines development are projected to boost the growth of the direct to consumer microbiome analysis market in the united states.

Which is the Key product type segment in the Direct to Consumer Microbiome Analyzing Market?

The gut microbiome test kits market is expected to increase at a faster rate. Future expansion will be aided by advancements in diagnostic tests as well as sequencing-based clinical microbiome analysis. Direct-to-consumer DNA testing is becoming more common, and it may now detect particular infections, lifestyle diseases, and gut ailments including irritable bowel syndrome and inflammatory bowel disease. These kits can be used for a variety of disease indications and applications, such as diarrhoea, irritable bowel syndrome, inflammatory bowel disease, and other gut-related disorders. Microbiome testing kits have seen a large growth in income due to the rising prevalence of chronic diseases and gut infections.

What are the Major Driving Factors for Direct to Consumer Microbiome Analyzing Market?

Increasing gastrointestinal problems, technological improvements, rising investments in human microbiome projects in developing nations, and the profitable presence of market players globally are factors driving the rapid growth of the global direct to consumer human microbiome analysis market. Over the projection period, the market will grow due to the increasing prevalence of genetic illnesses and different applications of direct to consumer microbiome analysis in primary identification of oncology, chronic diseases, infections, and other genetic disorders. The rising frequency of chronic diseases, as well as gut infections, has increased the revenue of microbiome testing kits globally, propelling the Direct to Consumer Microbiome Analysis market ahead. Furthermore, the growing older population and the rising frequency of lifestyle-related illnesses are two important drivers of market expansion.

What are the Major Restraints for Direct to Consumer Microbiome Analyzing Market?

Fewer treatment options, a lack of awareness about pipeline products in the DNA testing industry, and less positive outcomes are some of the factors restricting the worldwide growth of the direct to consumer microbiome analysis market. However, a lack of thorough research and stringent government regulations are projected to limit market growth throughout the projection period. Analyzing specific bacteria among trillions of species can be a difficult undertaking. High-throughput omics technology can identify the particular bacterial species involved and provide insight into how human-microbe balance is maintained. It necessitates a large amount of financing, which limits market expansion in undeveloped and developing economies.

Which Region Dominated the World Direct to Consumer Microbiome Analyzing Market?

In 2021, North America dominates the Direct to Consumer Microbiome Analyzing market over the forecast period due to a rise in the number of test kits available, as well as increased awareness of new technology that provides better results at a lower cost In the near future, the expansion will be driven by rising home care services and improved reimbursement structures. The market will rise due to rising prevalence of genetic disorders and various applications of direct to consumer microbiome Analyzing in primary detection of oncology, chronic diseases, infections, and other genetic disorders over the forecast period in this region. The majority of top firms in U.S. are concentrating on new product development and FDA approval. In the near future, the industry will be driven by an increasing number of partnerships with academic research centres and international alliances by leading laboratories. Many human microbiome-based product firms have received funding to help them create therapeutic medications. For instance, in 2020, the Biomedical Advanced Research and Development Authority (BARDA) awarded Vedanta Biosciences (US) USD 7.4 million in financing, with the prospect of an additional USD 69.5 million, to accelerate the clinical development of VE303 for high-risk Clostridioides difficile infection (CDI).

Europe is expected to have the highest growth rate over the forecast period. Factors like as rising prevalence of lifestyle illnesses, increased awareness of preventative healthcare, the availability of funding for microbiome research, and the increasing number of microbiome research and clinical activities are driving market expansion in this area. For instance, the European Commission established the Metagenomics of the Human Intestinal Tract (MetaHIT) initiative, which is primarily concerned with gut microorganisms. Similarly, Horizon 2020 is one of the largest EU Research and Innovation projects, with about USD 96.9 million (€80 billion) available over seven years (2014 to 2020).

Segmentation of Global Direct to Consumer Microbiome Analyzing Market-

Global Direct to Consumer Microbiome Analyzing Market – By Product Type

  • Gut Microbiome Test Kits
  • Other Microbiome Testing Kits & Health Sample Kits

Global Direct to Consumer Microbiome Analyzing Market – By Application

  • Infections
  • Gut Conditions
  • Metabolic Disorders
  • Cardiovascular Disease
  • Others

Frequently asked questions about the global Direct to Consumer Microbiome Analyzing industry

The global Direct to Consumer Microbiome Analyzing market is expected to be impacted significantly by COVID-19.

North America accounted for the highest share in the global Direct to Consumer Microbiome Analyzing market in terms of value.

The increasing frequency of genetic illnesses, as well as many applications of direct to consumer microbiome analysis in primary identification of oncology, chronic diseases, infections, and other genetic disorders, will drive market growth. The rising prevalence of chronic diseases and gut infections has increased the global revenue of microbiome testing kits, propelling the Direct to Consumer Microbiome Analysis market forward.

Gut microbiome test kits segment had a major share in 2021 with more than 40% of the market revenue share.

Gut conditions segment had a major share in 2021 with more than 30% of the market revenue share.

Direct to Consumer Microbiome Analyzing Market Scope

Report Attribute Details
Market Value in 2021 USD XX billion
Market Value in 2028 USD XX billion
CAGR 11.50%
Benchmarking Year 2021
Past data 2016 – 2021
Forecast period 2022 – 2028
Choose License Type
Budget Buying
Executive Summary - Brief Global Market Size - Current & Forecast
Regional Market Size - North America
Country Market Size - US
Company Profile – 1
Trusted By
Godaddy
Published Date:  Jul 2022
Category:  Biotechnology
Report ID:   59739
Report Format:   PDF
Pages:   180
Rating:    4.8 (72)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support